Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea
Completed
Aclaris Therapeutics, Inc.
Phase 4
2017-12-04
This study will evaluate the safety and tolerability of oxymetazoline HCl cream 1.0% when
used as an adjunctive treatment to energy-based therapy for participants with moderate to
severe persistent facial erythema associated with rosacea.
A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"
Completed
Teva Pharmaceuticals USA
Phase 3
2019-04-15
A Randomized, Double-blind, Parallel-group, Three-arm, Placebo-controlled, Multi-Site
Therapeutic Equivalence Study with Clinical End-points Comparing Test Product "Oxymetazoline
hydrochloride Cream, 1%" to Reference Product "RHOFADE™ Cream, 1%" in the Treatment of
Moderate to Severe Persistent Facial Erythema of Rosacea
A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"
Completed
Actavis Inc.
Phase 3
2019-04-15
A Randomized, Double-blind, Parallel-group, Three-arm, Placebo-controlled, Multi-Site
Therapeutic Equivalence Study with Clinical End-points Comparing Test Product "Oxymetazoline
hydrochloride Cream, 1%" to Reference Product "RHOFADE™ Cream, 1%" in the Treatment of
Moderate to Severe Persistent Facial Erythema of Rosacea
Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea
Recruiting
Candela Corporation
Phase 4
2019-01-15
This study will compare treatment outcome with pulsed dye laser, when used used as an
adjunctive treatment to oxymetazoline HCl 1% cream, compared to oxymetazoline HCL 1% cream
alone, for patients with moderate or severe erythematotelangiectatic rosacea.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
